The global rare hemophilia factors market is poised for substantial expansion, with projections indicating a market size of USD 490.4 million by the year 2030. This growth is expected to occur at a compound annual growth rate (CAGR) of 6.4% from 2025 to 2030, as detailed in a recent report by Grand View Research, Inc. A significant impetus for this market growth is the increasing number of factor concentrates that are receiving marketing approvals from regulatory bodies, most notably the U.S. Food and Drug Administration (FDA). These approvals are expected to provide a considerable boost to the market's expansion. Furthermore, the growing trend of patients adopting prophylactic treatment regimens is anticipated to further accelerate market growth in the coming years. Prophylactic treatment is strongly recommended for patients suffering from severe rare hemophilia factor disorders as it helps to prevent bleeding episodes and consequently improves their overall quality of life. The COVID-19 pandemic had a notable influence on the dynamics of this market.
The emphasis on patient safety and stringent infection control measures during the pandemic led to a heightened awareness and increased importance being placed on safety protocols in the administration of specific clotting factor therapies for rare hemophilia. Healthcare providers and patients alike became more vigilant in adhering to hygienic practices during treatment administration, including meticulous disinfection procedures, thorough hand hygiene, and the consistent use of personal protective equipment. This heightened focus on patient safety measures implemented during the pandemic is likely to have enduring positive effects on the administration of rare hemophilia factors in the long term. Despite the various challenges presented by the pandemic, the demand for specific clotting factor therapies for individuals with rare hemophilia remained consistently high. Patients with these rare hemophilia types continued to require these specialized therapies to effectively manage and treat their specific conditions.
Favorable initiatives and mandates implemented by governments to increase the rates of diagnosis and treatment for rare bleeding disorders are significantly contributing to market growth. For instance, the U.S. Congress enacted the Orphan Drug Act (ODA) in 1983. From its inception in 1983 up to 2015, approximately 3,647 drugs were granted the status of orphan drugs, and 554 of these drugs received approval from the U.S. FDA. Key players operating within the market are continuously engaging in various initiatives, such as the launch of innovative products and strategic collaborations, to gain a competitive edge in this highly competitive market environment. As an example, in November 2022, the FDA announced its approval of a groundbreaking gene therapy for the treatment of the genetic blood-clotting disorder Hemophilia B. This gene-based therapy, known as Kymriah, is specifically indicated for the treatment of B-cell precursor hemophilia patients under the age of 25 years.
Curious about the Rare Hemophilia Factors Market? Download your FREE sample copy now and get a sneak peek into the latest insights and trends.
Key highlights from the Rare Hemophilia Factors Market Report include:
• Factor VII deficiency held the largest share of the market in 2024, accounting for 35.1% of the total revenue. In contrast, Factor XIII deficiency is projected to experience the fastest compound annual growth rate (CAGR) of 7.1% over the forecast period, indicating a significant increase in its market presence.
• Recombinant therapies were the dominant product type in the market in 2024, capturing a revenue share of 50.3%. Looking ahead, prophylactic treatments are expected to register the fastest CAGR of 7.5% during the forecast period, highlighting the increasing adoption of preventative care strategies in managing rare hemophilia.
• Hospital pharmacies represented the largest distribution channel in 2024, holding a market share of 59.9%. However, online pharmacies are projected to be the fastest-growing distribution channel, with an anticipated CAGR of 9.2% over the forecast period, reflecting the increasing trend of online procurement of pharmaceuticals.
• North America dominated the global rare hemophilia factors market in 2024, accounting for the largest revenue share of 38.7%. However, the Asia Pacific rare hemophilia factors market is expected to register the fastest CAGR of 6.1% during the forecast period, indicating a significant growth potential in this region.
Key Rare Hemophilia Factors Companies:
The following are the leading companies in the rare hemophilia factors market. These companies collectively hold the largest market share and dictate industry trends.
• Takeda Pharmaceutical Company Limited
• Biogen
• Novo Nordisk A/S
• Bayer AG
• CSL
• Pfizer Inc.
• Sanofi
• F. Hoffmann-La Roche Ltd
• Swedish Orphan Biovitrum AB (publ)
• Octapharma AG
• Grifols, S.A.
• BioMarin
Order a free sample PDF of the Rare Hemophilia Factors Market Intelligence Study, published by Grand View Research.
